Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Group 1 - Cassava Sciences, Inc. will hold a conference call on November 7th at 8:30 a.m. Eastern Time [1] - The audio webcast of the conference call will be available on the company's website and can be replayed for 90 days [1] Group 2 - Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas, focused on detecting and treating neurodegenerative diseases, particularly Alzheimer's disease [2] - The company's drug candidate, Simufilam, is currently in Phase 3 clinical trials for Alzheimer's treatment and targets a specific site on filamin A [3] - Simufilam is believed to interrupt amyloid-β42 binding to receptors in the brain, potentially affecting the Alzheimer's disease process [3] - Cassava Sciences holds exclusive, worldwide rights to its investigational product candidates and related technologies without royalty obligations to third parties [3]